Kym is the global sector chair for health at Edelman, where she applies her experience in corporate communications, health care product marketing and issues management to the firm’s clients.
Before joining Edelman in 2011, shewas vice president of corporate communications for Baxter International Inc., a $13 billion global biopharmaceutical and medical products company. She held this role from 2007-2010.
Kym spent 16 years with Ogilvy PR Worldwide. During her tenure, she was managing director of the New York office and co-managing director of the agency’s global healthcare practice, which was well-known for brand and direct to consumer marketing.
Kym has been recognized as one of the top 50 healthcare PR professionals by PRWeek. She was elected to the Arthur Page Society in 2008, and elevated to its Board of Trustees in 2009.
Starting Monday, January 12th, nearly 5,000 healthcare company executives, analysts, institutional investors and assorted dealmakers will converge upon San Francisco to share their outlook for 2015 at the JP Morgan Healthcare Conference.
We are entering a new era in health that may not be fueled by blockbuster drugs for the masses, but one that will likely yield innovative therapies for our biggest health challenges, as well as well-placed optimism from investors and industry alike.
The leaders of Texas want to make it a state friendly for public-private partnerships, a destination for medical tourism and to attract innovators. But clearly, just as tort reform may deny remedies to people who need them most, a war for talent creates winners and losers.